AEON Biopharma, Inc. (AEON) - Total Liabilities
Based on the latest financial reports, AEON Biopharma, Inc. (AEON) has total liabilities worth $28.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AEON strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
AEON Biopharma, Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how AEON Biopharma, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AEON Biopharma, Inc. total assets.
AEON Biopharma, Inc. Competitors by Total Liabilities
The table below lists competitors of AEON Biopharma, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IQ Group Holdings Bhd
KLSE:5107
|
Malaysia | RM25.60 Million |
|
Northern Graphite Corporation
V:NGC
|
Canada | CA$105.66 Million |
|
Talisman Mining Ltd
AU:TLM
|
Australia | AU$1.00 Million |
|
Orange Minerals NL
AU:OMX
|
Australia | AU$623.65K |
|
AIRIQ INC.
F:EPXN
|
Germany | €1.05 Million |
|
Real Heart
ST:HEART
|
Sweden | Skr13.59 Million |
|
Nuvotec
KQ:060260
|
Korea | ₩32.17 Billion |
|
NextPoint Capital SOCIMI S.A.
MC:YNPC
|
Spain | €73.15 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down AEON Biopharma, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AEON net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AEON Biopharma, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AEON Biopharma, Inc. (2019–2024)
The table below shows the annual total liabilities of AEON Biopharma, Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $31.71 Million | -80.17% |
| 2023-12-31 | $159.89 Million | -43.14% |
| 2022-12-31 | $281.19 Million | +22.12% |
| 2021-12-31 | $230.26 Million | +2.59% |
| 2020-12-31 | $224.45 Million | +24.54% |
| 2019-12-31 | $180.22 Million | -- |
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of ga… Read more